CRISPR — short for clustered regularly interspaced short palindromic repeats — is a method of genetic editing that uses RNA ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Chantar, principal investigator at CIC bioGUNE and CIBERehd, has identified a new therapeutic target for cholangiocarcinoma ...

To solve a problem, we have to see it clearly. Whether it's an infection by a novel virus or memory-stealing plaques forming ...

Farmers, agronomists and industry leaders will converge on Kerang on Thursday, September 18, for the Spring Research Field ...

Arrowhead Pharmaceuticals ( (ARWR) ) has provided an announcement. On September 10, 2025, Arrowhead Pharmaceuticals filed a lawsuit against Ionis Pharmaceuticals in the United States District Court ...

The majority (16) of the top 20 players registered a decrease in market capitalisation in the second quarter of 2025.

Funding to accelerate the development of an innovative RNAi biocontrol technology to protect canola crops from crucifer and ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT ...

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company developing medicines that normalize the function of the ...

The deal opens up the possibility of future collaboration. Arrowhead moved a step closer to its aim of moving products into ...

In a significant validation of its technology, Arrowhead has entered a strategic agreement with Swiss pharmaceutical giant Novartis for its investigational RNAi therapeutic, ARO-SNCA. This preclinical ...